Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSD | P07339 | 1/20 | 0.45 |
| ▸ | SLC6A2 | P23975 | 17/20 | 0.40 |
| ▸ | SLC6A4 | P31645 | 17/20 | 0.40 |
| ▸ | SLC18A3 | Q16572 | 1/20 | 0.39 |
| ▸ | SLC6A3 | Q01959 | 9/20 | 0.37 |
| ▸ | KCNH2 | Q12809 | 4/20 | 0.37 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.37 |
| ▸ | GHSR | Q92847 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4763259 | 0.84 | CTSD (0.44) | CTSDSLC6A2SLC6A4SLC18A3SLC6A3 | |
| SCHEMBL6590138 | 0.82 | KMT2A (0.38) | SLC6A2SLC6A4SLC6A3KCNH2CYP2D6 | |
| SCHEMBL4767101 | 0.81 | CTSD (0.37) | CTSDSLC6A2SLC6A4SLC6A3KCNH2 | |
| SCHEMBL6589700 | 0.80 | SIGMAR1 (0.35) | SLC6A2SLC6A4SLC6A3KCNH2CYP2D6 | |
| SCHEMBL4765023 | 0.78 | CTSD (0.38) | CTSDSLC6A2SLC6A4SLC18A3SLC6A3 | |
| SCHEMBL2776534 | 0.75 | CTSD (0.55) | CTSDSLC6A2SLC6A4SLC18A3SLC6A3 | |
| SCHEMBL2776529 | 0.75 | CTSD (0.55) | CTSDSLC6A2SLC6A4SLC18A3SLC6A3 | |
| SCHEMBL7428571 | 0.74 | RPLP1 (0.33) | KCNH2 | |
| SCHEMBL4763258 | 0.74 | CTSD (0.38) | CTSDSLC6A2SLC6A4SLC18A3SLC6A3 | |
| SCHEMBL4763254 | 0.74 | CTSD (0.38) | CTSDSLC6A2SLC6A4SLC18A3SLC6A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1320370-A4 | METHOD OF TREATMENT | SMITHKLINE BEECHAM CORP (US) | 2008-10-22 | — | — | EP | disclosed |
| EP-1307204-A4 | PROTEASE INHIBITORS | SMITHKLINE BEECHAM CORP (US) | 2004-06-02 | — | — | EP | disclosed |
| EP-1320370-A1 | METHOD OF TREATMENT | SmithKline Beecham Corporation (US) | 2003-06-25 | — | — | EP | disclosed |
| EP-1307204-A1 | PROTEASE INHIBITORS | SmithKline Beecham Corporation (US) | 2003-05-07 | — | — | EP | disclosed |
| EP-1158986-A4 | PROTEASE INHIBITORS | SMITHKLINE BEECHAM CORP (US) | 2002-03-27 | — | — | EP | disclosed |
| WO-2002017924-A1 | METHOD OF TREATMENT | SMITHKLINE BEECHAM CORPORATION (GB) | 2002-03-07 | — | — | WO | disclosed |
| WO-2001095911-A1 | PROTEASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2001-12-20 | — | — | WO | disclosed |
| EP-1158986-A1 | PROTEASE INHIBITORS | SmithKline Beecham Corporation (US) | 2001-12-05 | — | — | EP | disclosed |
| WO-2000038687-A1 | PROTEASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2000-07-06 | — | — | WO | disclosed |